公开(公告)号：US20180346484A1

公开(公告)日：2018-12-06

申请号：US15882008

申请日：2018-01-29

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Irini Akritopoulou-Zanze ,  Wilfried Braje ,  Stevan W. Djuric ,  Noel S. Wilson ,  Sean C. Turner ,  Albert W. Kruger ,  Ana-Lucia Relo ,  Shashank Shekhar ,  Dennie S. Welch ,  Hongyu Zhao ,  Jorge Gandarilla ,  Alan F. Gasiecki ,  Huanqiu Li ,  Christina M. Thompson ,  Min Zhang

IPC: C07D513/04 ,  C07D495/16 ,  C07D487/04 ,  C07D495/04 ,  C07D491/04 ,  C07D491/044

CPC classification number: C07D513/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/044 ,  C07D495/04 ,  C07D495/16

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：US20160152600A1

公开(公告)日：2016-06-02

申请号：US15000017

申请日：2016-01-18

Applicant: AbbVie Inc.

Inventor： Todd S. McDermott ,  Seble H. Wagaw ,  Kenneth M. Engstrom ,  Jorge Gandarilla ,  Albert Kruger ,  Michael J. Rozema ,  Michael G. Fickes ,  Steven J. Wittenberger ,  Lakshmi Bhagavatula ,  Thomas B. Borchardt

IPC: C07D401/14 ,  C07F7/08 ,  C07D207/16 ,  C07D401/04 ,  C07D213/803

CPC classification number: C07D401/14 ,  C07D207/16 ,  C07D213/803 ,  C07D401/04 ,  C07F7/0803

Abstract: A process for making (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile and salts thereof, and intermediates used in the process are disclosed.

Abstract translation: 制备（2S，5R）-5-乙炔基-1- {N-（4-甲基-1-（4-羧基 - 吡啶-2-基）哌啶-4-基）甘氨酰基}吡咯烷-2-甲腈 及其盐，以及该方法中使用的中间体。

公开(公告)号：US09879033B2

公开(公告)日：2018-01-30

申请号：US14887171

申请日：2015-10-19

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Irini Akritopoulou-Zanze ,  Wilfried Braje ,  Stevan W. Djuric ,  Noel S. Wilson ,  Sean C. Turner ,  Albert W. Kruger ,  Ana-Lucia Relo ,  Shashank Shekhar ,  Dennie S. Welch ,  Hongyu Zhao ,  Jorge Gandarilla ,  Alan F. Gasiecki ,  Huanqiu Li ,  Christina M. Thompson ,  Min Zhang

IPC: A61K31/55 ,  C07D487/04 ,  C07D513/04 ,  C07D491/04 ,  C07D495/04 ,  C07D491/044 ,  C07D495/16

CPC classification number: C07D513/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/044 ,  C07D495/04 ,  C07D495/16

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：US20160096851A1

公开(公告)日：2016-04-07

申请号：US14887171

申请日：2015-10-19

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Irini Akritopoulou-Zanze ,  Wilfried Braje ,  Stevan W. Djuric ,  Noel S. Wilson ,  Sean C. Turner ,  Albert W. Kruger ,  Ana-Lucia Relo ,  Shashank Shekhar ,  Dennie S. Welch ,  Hongyu Zhao ,  Jorge Gandarilla ,  Alan F. Gasiecki ,  Huanqiu Li ,  Christina M. Thompson ,  Min Zhang

IPC: C07D513/04 ,  C07D491/044 ,  C07D495/16 ,  C07D487/04

CPC classification number: C07D513/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/044 ,  C07D495/04 ,  C07D495/16

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract translation: 本申请涉及式（I）的芳基 - 和杂芳基 - 稠合十氢吡咯并氮平，二氢八氢化吡咯并噻吩，十氢环庚三烯并[c]吡咯和八氢环庚三烯并[c]吡咯衍生物，其中R1，R2，R3，R4，R5，A，Y1 ，Y2和Y3如说明书中所定义。 本申请还涉及包含这些化合物的组合物，制备此类化合物的方法，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

公开(公告)号：US20140287992A1

公开(公告)日：2014-09-25

申请号：US14299095

申请日：2014-06-09

Applicant: Enanta Pharmaceuticals, Inc. ,  AbbVie, Inc.

Inventor： Hui-Ju Chen ,  Keith F. McDaniel ,  Brian E. Green ,  Jason P. Shanley ,  Albert W. Kruger ,  Jorge Gandarilla ,  Dennie S. Welch ,  Russell D. Cink ,  Steven C. Cullen ,  Yonghua Gai ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07K5/083

CPC classification number: C07K5/081 ,  C07D487/04

Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Abstract translation: 本发明涉及新的大环化合物和在需要用所述大环化合物进行这种治疗的受试者中治疗丙型肝炎感染的方法。 本发明还涉及包含本发明化合物或其药学上可接受的盐，酯或前药与药学上可接受的载体或赋形剂组合的药物组合物。

公开(公告)号：US09493506B2

公开(公告)日：2016-11-15

申请号：US14299095

申请日：2014-06-09

Applicant: Enanta Pharmaceuticals, Inc. ,  AbbVie, Inc.

Inventor： Hui-Ju Chen ,  Keith F. McDaniel ,  Brian E. Green ,  Jason P. Shanley ,  Albert W. Kruger ,  Jorge Gandarilla ,  Dennie S. Welch ,  Russell D. Cink ,  Steven C. Cullen ,  Yonghua Gai ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/04 ,  C07K5/083

CPC classification number: C07K5/081 ,  C07D487/04

Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.